Trial Profile

A Phase 2, Randomized, Double Crossover, Open-Label, Active-Controlled Proof-of-Concept Study of CNSA-001 in Phenylketonuria Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sepiapterin (Primary) ; Sapropterin
Indications Phenylketonuria
Focus Proof of concept; Therapeutic Use
Sponsors Censa Pharmaceuticals Australia

Most Recent Events

01 Mar 2022 Results published in the Metabolism - Clinical and Experimental
03 Dec 2019 Results presented in a Censa Pharmaceuticals Media Release.
03 Dec 2019 According to a Censa Pharmaceuticals media release, data will be presented at The American College of Medical Genetics and Genomics (ACMG) Meeting on March 18th, 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com